These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17005632)

  • 1. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
    Schadendorf D; Hauschild A; Ugurel S; Thoelke A; Egberts F; Kreissig M; Linse R; Trefzer U; Vogt T; Tilgen W; Mohr P; Garbe C
    Ann Oncol; 2006 Oct; 17(10):1592-7. PubMed ID: 17005632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
    Agarwala SS; Kirkwood JM; Gore M; Dreno B; Thatcher N; Czarnetski B; Atkins M; Buzaid A; Skarlos D; Rankin EM
    J Clin Oncol; 2004 Jun; 22(11):2101-7. PubMed ID: 15169796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
    Lewis KD; Gibbs P; O'Day S; Richards J; Weber J; Anderson C; Zeng C; Baron A; Russ P; Gonzalez R
    Cancer Invest; 2005; 23(4):303-8. PubMed ID: 16100942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases.
    Hofmann M; Kiecker F; Wurm R; Schlenger L; Budach V; Sterry W; Trefzer U
    J Neurooncol; 2006 Jan; 76(1):59-64. PubMed ID: 16132502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
    Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
    Hwu WJ; Lis E; Menell JH; Panageas KS; Lamb LA; Merrell J; Williams LJ; Krown SE; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
    Cancer; 2005 Jun; 103(12):2590-7. PubMed ID: 15861414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Spieth K; Kaufmann R; Dummer R; Garbe C; Becker JC; Hauschild A; Tilgen W; Ugurel S; Beyeler M; Bröcker EB; Kaehler KC; Pföhler C; Gille J; Leiter U; Schadendorf D
    Ann Oncol; 2008 Apr; 19(4):801-6. PubMed ID: 18178958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
    Larkin JM; Hughes SA; Beirne DA; Patel PM; Gibbens IM; Bate SC; Thomas K; Eisen TG; Gore ME
    Br J Cancer; 2007 Jan; 96(1):44-8. PubMed ID: 17146474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
    Bafaloukos D; Gogas H; Georgoulias V; Briassoulis E; Fountzilas G; Samantas E; Kalofonos Ch; Skarlos D; Karabelis A; Kosmidis P
    J Clin Oncol; 2002 Jan; 20(2):420-5. PubMed ID: 11786569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.
    Siena S; Crinò L; Danova M; Del Prete S; Cascinu S; Salvagni S; Schiavetto I; Vitali M; Bajetta E
    Ann Oncol; 2010 Mar; 21(3):655-661. PubMed ID: 19767314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma.
    Bafaloukos D; Tsoutsos D; Fountzilas G; Linardou H; Christodoulou C; Kalofonos HP; Briassoulis E; Panagiotou P; Hatzichristou H; Gogas H
    Melanoma Res; 2004 Aug; 14(4):289-94. PubMed ID: 15305160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
    Brada M; Judson I; Beale P; Moore S; Reidenberg P; Statkevich P; Dugan M; Batra V; Cutler D
    Br J Cancer; 1999 Nov; 81(6):1022-30. PubMed ID: 10576660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
    Frick S; Lischner S; Rosien F; Haacke TC; Schäfer F; Christophers E; Hauschild A
    Hautarzt; 2002 Oct; 53(10):659-65. PubMed ID: 12297947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of temozolomide using an extended continuous oral schedule.
    Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
    Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.
    McQuade JL; Posada LP; Lecagoonporn S; Cain S; Bassett RL; Patel SP; Hwu WJ; Hwu P; Davies MA; Bedikian AY; Amaria RN
    Melanoma Res; 2016 Dec; 26(6):604-608. PubMed ID: 27540836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).
    Guida M; Tommasi S; Strippoli S; Natalicchio MI; De Summa S; Pinto R; Cramarossa A; Albano A; Pisconti S; Aieta M; Ridolfi R; Azzariti A; Guida G; Lorusso V; Colucci G
    BMC Cancer; 2018 May; 18(1):552. PubMed ID: 29747595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
    Patel PM; Suciu S; Mortier L; Kruit WH; Robert C; Schadendorf D; Trefzer U; Punt CJ; Dummer R; Davidson N; Becker J; Conry R; Thompson JA; Hwu WJ; Engelen K; Agarwala SS; Keilholz U; Eggermont AM; Spatz A;
    Eur J Cancer; 2011 Jul; 47(10):1476-83. PubMed ID: 21600759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
    Chiarion-Sileni V; Guida M; Ridolfi L; Romanini A; Del Bianco P; Pigozzo J; Brugnara S; Colucci G; Ridolfi R; De Salvo GL;
    Br J Cancer; 2011 Jun; 104(12):1816-21. PubMed ID: 21610711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic melanoma: a regional review and future directions.
    Khan KH; Goody RB; Hameed H; Jalil A; Coyle VM; McAleer JJ
    Tumori; 2012; 98(5):575-80. PubMed ID: 23235751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
    Bael TE; Peterson BL; Gollob JA
    Melanoma Res; 2008 Apr; 18(2):147-51. PubMed ID: 18337652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.